0001279569-24-000137.txt : 20240213 0001279569-24-000137.hdr.sgml : 20240213 20240213070141 ACCESSION NUMBER: 0001279569-24-000137 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240213 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240213 DATE AS OF CHANGE: 20240213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ESSA Pharma Inc. CENTRAL INDEX KEY: 0001633932 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37410 FILM NUMBER: 24622557 BUSINESS ADDRESS: STREET 1: SUITE 720 STREET 2: 999 WEST BROADWAY CITY: VANCOUVER STATE: A1 ZIP: V5Z 1K5 BUSINESS PHONE: (778) 331-0962 MAIL ADDRESS: STREET 1: SUITE 720 STREET 2: 999 WEST BROADWAY CITY: VANCOUVER STATE: A1 ZIP: V5Z 1K5 8-K 1 form8k.htm FORM 8-K
false 0001633932 A1 0001633932 2024-02-13 2024-02-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

- - - - - - - - -

FORM 8-K

- - - - - - - - -

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): February 13, 2024

- - - - - - - - -

ESSA Pharma Inc.

(Exact name of registrant as specified in its charter)

- - - - - - - - -

British Columbia, Canada

(State or other jurisdiction of incorporation)

001-37410

(Commission File Number)

98-1250703

(IRS Employer Identification No.)

     

Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada

(Address of principal executive offices)

V5Z 1K5

(Zip Code)

 

Registrant’s telephone number, including area code: (778) 331-0962

- - - - - - - - -

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Shares, no par value EPIX Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
 

Item 2.02 Results of Operations and Financial Condition.

 

The following information is filed pursuant to Item 2.02, “Results of Operations and Financial Condition.”

 

On February 13, 2024, ESSA Pharma Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2023. A copy of the press release is attached as Exhibit 99.1 to this Form 8-K.

 

The information provided under this Item (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

 

 

Item 9.01 Financial Statements and Exhibits.
   
  (d) Exhibits

 

Exhibit No.

  

Description

  
99.1   Press Release dated February 13, 2024  
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)  
 
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ESSA PHARMA INC.

(Registrant)

 

 

Date: February 13, 2024

 

By: /s/ David Wood

Name:       David Wood

Title:       Chief Financial Officer

 

 

 

 EX-101.LAB 2 epix-20240213_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 3 epix-20240213_pre.xml XBRL PRESENTATION FILE EX-101.SCH 4 epix-20240213.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-99.1 5 ex991.htm NEWS RELEASE DATED FEBRUARY 13, 2024

Exhibit 99.1

 

 

 

 

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023

 

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63% of patients achieving PSA <0.2ng/mL

 

Phase 2 masofaniten plus enzalutamide combination dose expansion study ongoing

 

Cash runway sufficient to fund operations beyond 2025

 

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 13, 2024 - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2023.

 

"As we enter 2024, we are focused on advancing the investigation of masofaniten in combination with second-generation antiandrogen agents, with the goal of improving clinical outcomes for patients battling prostate cancer," said David Parkinson, MD, President and CEO of ESSA. "We are extremely pleased with the data reported to date from the Phase 1 dose escalation study evaluating masofaniten combined with enzalutamide in patients with mCRPC naïve to second generation anti-androgens where we continue to observe compelling, deep and durable reductions in prostate-specific antigen ("PSA"), along with an encouraging 16.6 month median time to PSA progression. We look forward to reporting updated Phase 1 dose escalation data during 2024. In addition, we continue to advance enrollment in both Phase 1 arms evaluating masofaniten in combination with apalutamide or abiraterone acetate, respectively, and look forward to reporting preliminary data during the second half of 2024."

 

"On the financial front, we are bolstered by our strong cash position that we expect will provide sufficient runway to fund our planned operations through several data readouts and beyond 2025. We are excited to execute on our key 2024 objectives which we believe will meaningfully advance the investigation of masofaniten and look forward to providing updates on our progress throughout the year," concluded Dr. Parkinson.

 

First Quarter Fiscal 2024 and Recent Highlights

 

Masofaniten Combination Studies

 

•Reported Phase 1 dose escalation data at multiple medical meetings from the four cohorts of its ongoing Phase 1/2 study evaluating masofaniten in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer ("mCRPC") naïve to second-generation antiandrogens but may have been treated with chemotherapy in the metastatic castration-sensitive setting.
 
 

 

These data were presented at the 2024 ASCO Genitourinary Cancers Symposium, the 2023 Prostate Cancer Foundation Scientific Retreat and at the European Society for Medical Oncology 2023 Congress. As of the most recent data presentation, the results demonstrated that the combination continues to be well tolerated at the dose levels tested through up to 25 cycles of dosing in some patients. Deep and durable reductions in PSA were observed across evaluable patients for efficacy in all dosing cohorts (n=16). Across all dosing cohorts, 88% of patients achieved PSA50, 81% of patients achieved PSA90, 69% of patients achieved PSA90 in less than 90 days, and 63% of patients achieved PSA <0.2ng/mL. While the data for time to PSA progression are still maturing with a current median follow up of 11.1 months, the median time to PSA progression is 16.6 months. ESSA expects to report updated data from the Phase 1 dose escalation study during the second half of 2024.

•Enrollment is underway in the Phase 2 portion of the Phase 1/2 study evaluating the combination of masofaniten and enzalutamide compared to enzalutamide monotherapy in patients with mCRPC naïve to second-generation antiandrogens but who may have been treated with chemotherapy in the metastatic castration-sensitive setting. The Phase 2 portion of the study is an open-label randomized study comparing 160 mg once-daily of single agent enzalutamide to the combination of masofaniten with enzalutamide, and is expected to enroll approximately 120 patients. The recommended Phase 2 combination dose was identified as masofaniten 600 mg twice-daily combined with enzalutamide 160 mg once daily. The study is currently enrolling at approximately 25 sites in the USA, Canada and Australia. Expansion to European sites is in progress. ESSA plans to provide guidance for timing of the public disclosure of initial data once the Phase 2 portion has been underway for several months.
•Initiated two additional masofaniten combination arms as part of the ongoing Phase 1 masofaniten study. One arm will evaluate masofaniten in combination with abiraterone acetate and prednisone in patients with either metastatic castration-sensitive prostate cancer or mCRPC while the second arm will evaluate masofaniten in combination with apalutamide in patients with non-metastatic castration-resistant prostate cancer after 12 weeks of masofaniten single agent. ESSA expects to report preliminary data from these Phase 1 arms during the second half of 2024.
•An investigator-sponsored neoadjuvant study was also initiated evaluating neoadjuvant use of the combination of masofaniten and darolutamide compared to darolutamide monotherapy in high-risk patients undergoing prostatectomy.

Masofaniten Monotherapy Study

 

•On track to complete the Phase 1b masofaniten monotherapy study evaluating masofaniten in patients with late-line mCRPC, which is currently ongoing. The initial results from the study were reported at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, which demonstrated that masofaniten monotherapy was well-tolerated, achieved clinically significant exposures, and showed preliminary signals of anti-tumor activity in a subset of patients. ESSA plans to present the complete Phase 1a and 1b monotherapy results in 2024 at a medical conference.
 
 

 

Summary Financial results

(Amounts expressed in U.S. dollars)

 

•Net Loss. ESSA recorded a net loss of $6.0 million for the first quarter ended December 31, 2023 compared to $6.7 million for the first quarter ended December 31, 2022. The decrease in the first quarter was primarily attributed to an increase in investment income over the prior period of $0.5 million.
•Research and Development ("R&D") expenditures. R&D expenditures for the first quarter ended December 31, 2023 were $5.4 million compared to $5.3 million for the first quarter ended December 31, 2022, and include non-cash costs related to share-based payments $526,241 for the first quarter ended 2023 compared to $791,192 for the first quarter ended 2022. Reduced expenditure on manufacturing for the period was offset by additional investment in the clinical trial work on masofaniten.
•General and Administration ("G&A") expenditures. G&A expenditures for the first quarter ended December 31, 2023 were $2.2 million compared to $2.5 million for the first quarter ended December 31, 2022 and include non-cash costs related to share-based payments of $277,177 for the first quarter ended 2023 compared to $772,419 for the first quarter ended 2022. The overall expenditure is largely comparable to the Company's additional spend on professional fees to update Company's documents for its shelf prospectus and ATM program.

Liquidity and Outstanding Share Capital

 

•As of December 31, 2023, the Company had available cash reserves and short-term investments of $142.1 million. The Company's cash position is expected to be sufficient to fund current and planned operations beyond 2025.
•On November 6, 2023, the Company announced that it had entered into an Open Market Sale AgreementSM (the "ATM Sales Agreement") with Jefferies LLC, effective as of November 3, 2023. Under the ATM Sales Agreement, ESSA may, within the period that the ATM Sales Agreement is in effect, sell its common shares from time to time for up to $50.0 million in aggregate sales proceeds. No offers or sales of common shares will be made in Canada, to anyone known by Jefferies LLC to be a resident of Canada or on or through the facilities of any stock exchange or trading markets in Canada.
•As of December 31, 2023, the Company had 44,163,647 common shares issued and outstanding.
•In addition, as of December 31, 2023, there were 2,920,000 common shares issuable upon the exercise of prefunded warrants at an exercise price of $0.0001.

 

 

About ESSA Pharma Inc.

 

ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com, and follow us on Twitter and LinkedIn.

 

Forward-Looking Statement Disclaimer

 

This release contains certain information which, as presented, constitutes "forward-looking information" within the meaning of the Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities laws. Forward-looking information involves statements that relate to future events and often addresses expected future business and financial performance, containing words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions and includes, but is not limited to, statements regarding the Company’s plans to report updated data from its studies, the Company’s advancement and evaluation of masofaniten, the timing of the Company’s studies, enrollment in the Company’s studies, the presentation of Phase 1a and 1b monotherapy results, sales of common shares pursuant to the ATM Sales Agreement and the Company’s expected cash runway.

 

Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied thereby. Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. In making forward looking statements, ESSA may make various material assumptions, including but not limited to (i) the accuracy of ESSA's financial projections; (ii) obtaining positive results of clinical trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market and economic conditions.

 

Forward-looking information is developed based on assumptions about such risks, uncertainties and other factors set out herein and in ESSA's Annual Report on Form 10-K dated December 12, 2023, under the heading "Risk Factors", a copy of which is available on ESSA's profile on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca, and as otherwise disclosed from time to time on ESSA's EDGAR and SEDAR+ profiles. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may be required by applicable United States and Canadian securities laws. Readers are cautioned against attributing undue certainty to forward-looking statements.

 

Contacts

 

ESSA Pharma, Inc.

David Wood, Chief Financial Officer

778.331.0962

dwood@essapharma.com

 

Investors and Media:

Argot Partners

212.600.1902

essa@argotpartners.com

 
 

 

 

ESSA PHARMA INC.

CONSOLIDATED BALANCE SHEETS

Amounts in thousands of United States dollars

 

  December 31, 2023 September 30, 2023
     
Cash and cash equivalents $ 35,345 $ 33,702
Prepaids and other assets 109,144 115,420
     
Total assets $ 144,489 $ 149,122
     
Current liabilities 3,531 3,495
Long-term debt 275 -
Shareholders' equity 140,683 145,627
     
Total liabilities and shareholders' equity $ 144,489 $ 149,122

 

 
 

 

ESSA PHARMA INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

Amounts in thousands of United States dollars, except share and per share data

  Three months ended December 31, 2023 Three months ended December 31, 2022
     
OPERATING EXPENSES    
Research and development $ 5,377 $ 5,344
Financing costs - 3
General and administration 2,218 2,519
     
Total operating expenses (7,595) (7,866)
     
Investment income and other items 1,631 1,124
     
Net loss for the period $ (5,964) $ (6,742)
     
OTHER COMPREHENSIVE LOSS    
     
Unrealized gain on short-term investments 20 30
     
Loss and comprehensive loss for the period $ (5,944) $ (6,712)
     
Basic and diluted loss per common shares $ (0.14) $ (0.15)
     
Weighted average number of common shares outstanding 44,129,491 44,073,286

 

 

 

 GRAPHIC 6 logo.jpg GRAPHIC begin 644 logo.jpg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htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Feb. 13, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 13, 2024
Entity File Number 001-37410
Entity Registrant Name ESSA Pharma Inc.
Entity Central Index Key 0001633932
Entity Tax Identification Number 98-1250703
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One Suite 720
Entity Address, Address Line Two 999 West Broadway
Entity Address, City or Town Vancouver
Entity Address, State or Province BC
Entity Address, Country CA
Entity Address, Postal Zip Code V5Z 1K5
City Area Code 778
Local Phone Number 331-0962
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol EPIX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://essapharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports epix-20240213.xsd epix-20240213_lab.xml epix-20240213_pre.xml form8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8k.htm": { "nsprefix": "EPIX", "nsuri": "http://essapharma.com/20240213", "dts": { "schema": { "local": [ "epix-20240213.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "epix-20240213_lab.xml" ] }, "presentationLink": { "local": [ "epix-20240213_pre.xml" ] }, "inline": { "local": [ "form8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://essapharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-02-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-02-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001279569-24-000137-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001279569-24-000137-xbrl.zip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form8k_htm.xml IDEA: XBRL DOCUMENT 0001633932 2024-02-13 2024-02-13 iso4217:USD shares iso4217:USD shares false 0001633932 A1 8-K 2024-02-13 ESSA Pharma Inc. 001-37410 98-1250703 Suite 720 999 West Broadway Vancouver BC CA V5Z 1K5 778 331-0962 false false false false Common Shares, no par value EPIX NASDAQ false